<div id="readability-page-1"><p>William Blair analyst Sami Corwin has reiterated their neutral  stance on <span>QURE</span> stock, giving a Hold rating on January 28.</p><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock  hedge fund-level data  and  powerful investing tools  for smarter, sharper decisions  </li><li> Stay ahead of the market with  the latest news and analysis  and maximize your portfolio's potential</li></ul> <div><p>Sami Corwin has given his Hold rating due to a combination of factors related to both opportunity and uncertainty in uniQure’s pipeline. The new Fabry disease data for AMT-191 are directionally positive, showing strong and durable enzyme activity as well as a meaningful proportion of patients able to discontinue enzyme replacement therapy, which supports the potential of this asset. At the same time, a competing Fabry gene therapy from Sangamo is further along, with a rolling BLA already underway and supported by an endpoint (eGFR) that uniQure has not yet reported for AMT-191, tempering the near-term competitive positioning.</p><p>  Corwin also emphasizes that investor attention is centered on the future of AMT-130, where regulatory clarity will be a major driver of the stock. While upcoming interactions with regulators could be a catalyst, there is currently no defined timeline or clear path toward a BLA or similar filing for AMT-130, leaving a high degree of strategic and regulatory uncertainty. This mix of encouraging but early-stage data for AMT-191 and an unclear development trajectory for AMT-130 leads Corwin to view the risk/reward as balanced rather than compellingly skewed to the upside, supporting the decision to maintain a Hold (Market Perform) rating on uniQure shares.</p></div> <p>According to TipRanks, Corwin is a 5-star analyst with an average return of <span>13.0%</span> and a 49.62% success rate. Corwin covers the Healthcare sector, focusing on stocks such as Solid Biosciences, Applied Therapeutics, and Cabaletta Bio.</p> <p>In another report released on January 28, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $25.00 price target.</p></div>

IBBQ

SBIO

SGMO

LABD

<p>William Blair analyst Sami Corwin maintains a Hold rating on uniQure (QURE) stock, citing a balanced risk/reward scenario. Positive data for AMT-191 shows strong enzyme activity, but competition from Sangamo's advanced Fabry gene therapy tempers optimism. Uncertainty surrounds AMT-130's regulatory path, with no clear timeline for a BLA filing. Corwin's analysis reflects cautious optimism, leading to a neutral stance on the stock. TipRanks also supports a Hold rating with a $25.00 price target.</p>

Tip Ranks

VanEck Biotech ETF

First Trust NYSE Arca Biotech Index Fd

Invesco Nasdaq Biotechnology ETF

ALPS Medical Breakthrough

Sangamo Therap

Direxion S&P Biotech Bear 3X

Invesco Biotechnology & Genome ETF

Proshares Ultra Nasdaq Biotech

Balanced Risk/Reward at uniQure: Early Promise for AMT-191 Offset by Regulatory and Competitive Uncertainty Around AMT-130